We report the isolation and characterization of three new nybomycins (nybomycins B-D, -) and six known compounds (nybomycin, ; deoxynyboquinone, ; α-rubromycin, ; β-rubromycin, ; γ-rubromycin, ; and [2α(1,3),4β]-2-(1,3-pentadienyl)-4-piperidinol, ) from the Rock Creek (McCreary County, KY) underground coal mine acid reclamation site isolate sp. AD-3-6. Nybomycin D () and deoxynyboquinone () displayed moderate () to potent () cancer cell line cytotoxicity and displayed weak to moderate anti-Gram-(+) bacterial activity, whereas rubromycins - displayed little to no cancer cell line cytotoxicity but moderate to potent anti-Gram-(+) bacterial and antifungal activity. Assessment of the impact of or cancer cell line treatment on 4E-BP1 phosphorylation, a predictive marker of ROS-mediated control of cap-dependent translation, also revealed deoxynyboquinone ()-mediated downstream inhibition of 4E-BP1p. Evaluation of - in a recently established axolotl embryo tail regeneration assay also highlighted the prototypical telomerase inhibitor γ-rubromycin () as a new inhibitor of tail regeneration. Cumulatively, this work highlights an alternative nybomycin production strain, a small set of new nybomycin metabolites, and previously unknown functions of rubromycins (antifungal activity and inhibition of tail regeneration) and also provides a basis for revision of the previously proposed nybomycin biosynthetic pathway.